TrialPloS one2011

Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study.

Øystein Fluge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.